A step closer to Phase IIb for CS014

Cereno Scientific has cleared another important execution milestone for CS014, completing participant dosing and follow-up in its Phase I pharmacokinetic (PK) bridging study (n=14). The programme remains on track for a Q326 top-line readout following database lock and analysis, with supportive data expected to underpin the planned H226 investigational new drug submission and potentially enable a direct transition into Phase IIb (in 2027), bypassing additional non-clinical safety studies and the conventional Phase IIa step. If successful, we expect this to materially improve the programme’s development economics by reducing both timelines and capital requirements, while accelerating the first efficacy evaluation in pulmonary hypertension...